News for PD-Rx Pharmaceuticals, Inc. (PDRX)

Cedar Creek’s average annual return over our 19 year history is 14.0%, net of fees and expenses, which compares favorably to all the indices we compare against.

For the first time in a while, the NASDAQ was not the best performing of the major indices.

Cedar Creek increased by 2.5% in the second quarter, and 4.9% year-to-date, net of fees and expenses. Click here to read the full fund letter.

Cedar Creek increased by 2.4% in the first quarter of 2024, net of fees and expenses. Click here to read the full fund letter.

Cedar Creek increased by 2.8% in the fourth quarter, and was up 20.3% for 2023, net of fees and expenses. Click here to read the full fund letter.

Cedar Creek increased by 12.5% in Q3 2023, and was up 16.7% for the first 9 months of 2023, net of fees and expenses. Click here to read the full fund letter.

While some opportunities are very attractive, we had yet to come across one we were hoping for, but that changed in the quarter. What was this opportunity? Find out.

yucelyilmazDear Partners and Friends:The NASDAQ continued to destroy the other major US indices in the second quarter and the first half of 2023.

As of March-end 2023, Cedar Creek Partners' holdings were trading at 5.1 times our estimate of earnings for the coming year.

Cedar Creek increased by 6.2% in Q4 2022, and was up 8.8% in 2022, both net of fees and expenses. Click here to read the full fund letter.

Cedar Creek increased by 13.4% in Q3 2022 and was up 2.4% in the first nine months (net of fees and expenses), Click here to read the full fund letter.

Cedar Creek declined by 10.2% in the second quarter 2022, net of fees and expenses. Click here to read the full fund letter.